Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELVN 
Enliven Therapeutics Inc. (ELVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ELVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $41.25
1 Year Target Price $41.25
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.07% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.21B USD | Price to earnings Ratio - | 1Y Target Price 41.25 |
Price to earnings Ratio - | 1Y Target Price 41.25 | ||
Volume (30-day avg) 8 | Beta 1.03 | 52 Weeks Range 13.30 - 30.03 | Updated Date 08/29/2025 |
52 Weeks Range 13.30 - 30.03 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.99 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.55 | Actual -0.49 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.19% | Return on Equity (TTM) -25.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 716112736 | Price to Sales(TTM) - |
Enterprise Value 716112736 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.28 | Shares Outstanding 59235500 | Shares Floating 36320276 |
Shares Outstanding 59235500 | Shares Floating 36320276 | ||
Percent Insiders 8.88 | Percent Institutions 102.16 |
Upturn AI SWOT
Enliven Therapeutics Inc.
Company Overview
History and Background
Enliven Therapeutics, Inc. is a clinical-stage precision oncology company focused on discovering and developing small molecule kinase inhibitors. Founded to address significant unmet needs for cancer patients, Enliven's focus is on novel therapies for cancers driven by kinase mutations. The company aims to create highly selective and potent kinase inhibitors that can improve outcomes for patients with limited treatment options.
Core Business Areas
- Oncology Drug Development: Enliven's primary business is the discovery, development, and commercialization of small molecule kinase inhibitors for cancer treatment. This includes preclinical research, clinical trials, and regulatory submissions.
Leadership and Structure
The leadership team consists of experienced executives in drug development and oncology. The company structure is typical of a biotech company, with departments focused on research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- ELVN-3231: ELVN-3231 is a KRAS G12D selective inhibitor in Phase 1 clinical development for patients with KRAS G12D-mutant cancers. The KRAS G12D mutation is prevalent in lung, colorectal, and pancreatic cancers. Competitors include Mirati Therapeutics (MRTX) and other companies pursuing KRAS inhibitors.
- ELVN-3106: ELVN-3106 is a selective small molecule inhibitor of mutant HER2, designed to address resistance to existing HER2-targeted therapies. It's in preclinical development. Competitors include Daiichi Sankyo (DSKYF) and AstraZeneca (AZN) with their HER2-targeted therapies.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market driven by increasing cancer incidence and advancements in cancer treatment. Precision oncology, focusing on targeted therapies for specific genetic mutations, is a key trend.
Positioning
Enliven Therapeutics is positioned as a precision oncology company focused on developing highly selective kinase inhibitors for specific cancer mutations. Their competitive advantage lies in their novel drug candidates and expertise in kinase inhibitor development.
Total Addressable Market (TAM)
The TAM for KRAS G12D and HER2 targeted therapies are multibillion-dollar markets. Enliven is positioned to capture a portion of these markets with successful clinical trials and commercialization of their drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting specific cancer mutations
- Experienced leadership team
- Strong intellectual property portfolio
- Precision oncology focus
Weaknesses
- Early stage clinical development (high risk)
- Dependence on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- No currently approved products
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to additional cancer targets
- FDA fast-track designation or breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from other companies developing similar therapies
- Regulatory hurdles
- Changes in the healthcare landscape and reimbursement policies
Competitors and Market Share
Key Competitors
- MRTX
- AZN
- DSKYF
- LLY
Competitive Landscape
Enliven is currently in early stages. MRTX, AZN, DSKYF and LLY have approved products and greater resources. Enliven's advantage is their novel approach for the selected targets and patient populations.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as Enliven is a relatively new company.
Future Projections: Future growth is dependent on successful clinical development and potential commercialization of their drug candidates. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing ELVN-3231 and ELVN-3106 through clinical trials and preclinical studies, respectively. They are also presenting data at major oncology conferences and seeking partnerships to further their development efforts.
Summary
Enliven Therapeutics is a clinical-stage precision oncology company focusing on novel therapies. Their future heavily depends on positive clinical trial results. They have a strong focus on specific kinase inhibitors and are positioned to address significant unmet needs. The company faces challenges common to early-stage biotechs, including competition, regulatory hurdles, and reliance on fundraising. Success will require significant advancement of the pipeline and execution of trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Enliven Therapeutics Inc. website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in biotech companies involves significant risks, including clinical trial failures and regulatory setbacks. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enliven Therapeutics Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2020-03-12 | Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | |
Full time employees 63 | |||
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.